- Home
- CVRX vs SGHT Comparison
CVRX vs SGHT Comparison
Compare CVRX & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVRX
- SGHT
- Stock Information
- Founded
- CVRX 2000
- SGHT 2011
- Country
- CVRX United States
- SGHT United States
- Employees
- CVRX N/A
- SGHT N/A
- Industry
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- SGHT Medical Specialities
- Sector
- CVRX Health Care
- SGHT Health Care
- Exchange
- CVRX Nasdaq
- SGHT Nasdaq
- Market Cap
- CVRX 174.4M
- SGHT 179.7M
- IPO Year
- CVRX 2021
- SGHT 2021
- Fundamental
- Price
- CVRX $7.56
- SGHT $3.27
- Analyst Decision
- CVRX Buy
- SGHT Buy
- Analyst Count
- CVRX 7
- SGHT 8
- Target Price
- CVRX $14.50
- SGHT $3.87
- AVG Volume (30 Days)
- CVRX 302.9K
- SGHT 123.7K
- Earning Date
- CVRX 08-04-2025
- SGHT 08-07-2025
- Dividend Yield
- CVRX N/A
- SGHT N/A
- EPS Growth
- CVRX N/A
- SGHT N/A
- EPS
- CVRX N/A
- SGHT N/A
- Revenue
- CVRX $52,870,000.00
- SGHT $78,109,000.00
- Revenue This Year
- CVRX $11.53
- SGHT N/A
- Revenue Next Year
- CVRX $18.61
- SGHT $11.22
- P/E Ratio
- CVRX N/A
- SGHT N/A
- Revenue Growth
- CVRX 25.62
- SGHT N/A
- 52 Week Low
- CVRX $4.30
- SGHT $2.03
- 52 Week High
- CVRX $18.55
- SGHT $7.78
- Technical
- Relative Strength Index (RSI)
- CVRX 50.10
- SGHT 39.19
- Support Level
- CVRX $8.10
- SGHT $3.41
- Resistance Level
- CVRX $8.81
- SGHT $3.63
- Average True Range (ATR)
- CVRX 0.58
- SGHT 0.19
- MACD
- CVRX -0.06
- SGHT -0.02
- Stochastic Oscillator
- CVRX 29.89
- SGHT 23.19
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.